– USA, CA – Prometheus Biosciences, Inc. (Nasdaq: RXDX) today announced the appointment of Fred Hassan to its Board of Directors.
The company is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease.
“We’re honored to have a highly accomplished industry titan like Fred join our Board at this pivotal time,” said CEO, Mark McKenna. “Fred’s wealth of experience over the last thirty years as an investor, board member, and executive of global pharmaceutical corporations, will strengthen our board as we advance our pipeline of precision therapies for immune-mediated diseases. On behalf of the Board, I welcome Fred and we are eager to benefit from his insights and acumen.”
About Fred Hassan
Fred Hassan joined Warburg Pincus LLC, a global private equity investment institution, in 2009 and currently serves as Director. Previously, Mr. Hassan served as Chairman and CEO of Schering-Plough from 2003 to 2009. Before assuming these roles, from 2001 to 2003, Mr. Hassan was Chairman and CEO of Pharmacia Corporation, a company formed through the merger of Monsanto Company and Pharmacia & Upjohn, Inc. He joined Pharmacia & Upjohn, Inc. as CEO in 1997.
Mr. Hassan has been a director of Amgen, Inc. since 2015 and of Precigen Corporation, a synthetic biology company, since 2016. He was a director of Time Warner Inc. from 2009 until its acquisition by AT&T Inc. in 2018 and a director of Avon Products, Inc. from 1999 until 2013, where he served as Chairman of the Board between January and April 2013. He was Chairman of the Board of Bausch & Lomb from 2010 until its acquisition by Valeant Pharmaceuticals International, Inc. in 2013 and served on the board of Valeant Pharmaceuticals from 2013 to 2014.
Fred Hassan commented, “Prometheus has great potential to disrupt the immune-mediated disease space and industry as a whole. I’m impressed with their clinical-stage pipeline, the Prometheus360TM platform, as well as their strong financial position following their recent IPO. I look forward to working closely with the Prometheus leadership and board as they transform patients’ lives by applying their precision approach to IBD and beyond.”
Mr. Hassan received an undergraduate degree from Imperial College of Science and Technology, University of London, and a master’s degree in business administration from Harvard Business School.
About Prometheus Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD. The Company’s precision medicine platform, Prometheus360TM, combines proprietary bioinformatics discovery methods with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.
For more information: https://www.prometheusbiosciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.